GlassScriptPhysician profile
Kristina M Semidey
NPI 1821484197
$1,587.21
in general payments reported to CMS, 2019-2025
29 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $423 · 2021: $57.99 · 2022: $405 · 2023: $192 · 2024: $227 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $218.11 | 2020-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $163.81 | 2019-2025 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $121.76 | 2022 | |
| Mylan Specialty L.P. | $110.00 | 2020 | |
| Abbvie INC. | $89.80 | 2022-2025 | |
| Novo Nordisk INC | $83.80 | 2020-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $66.81 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.41 | 2020-2024 | Ofev |
| Otsuka America Pharmaceutical, INC. | $54.93 | 2022 | |
| Sumitomo Pharma America, INC. | $52.24 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $49.57 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $48.42 | 2022-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $42.36 | 2020-2022 | |
| Exact Sciences Corporation | $41.50 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $39.28 | 2021-2024 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.18 | 2020-2022 | |
| Lilly USA, LLC | $33.13 | 2022-2023 | Mounjaro |
| Mannkind Corporation | $32.80 | 2022 | |
| Pfizer INC. | $31.82 | 2024-2025 | |
| Shield Therapeutics INC | $27.92 | 2023 | Accrufer |
| Insulet Corporation | $24.84 | 2025 | Omnipod |
| Gilead Sciences, INC. | $22.36 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.79 | 2023 | Quviviq |
| Ferring Pharmaceuticals INC. | $21.32 | 2023 | Rebyota |
| Kowa Pharmaceuticals America, INC. | $20.95 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.23 | 2024 | Voquezna |
| Amgen INC. | $15.58 | 2022 | |
| Daiichi Sankyo INC. | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Semidey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.